GlassScriptPhysician profile
Shuxin Li
NPI 1982812269
$2,957.18
in general payments reported to CMS, 2019-2025
19 companies · $333 in 2025
The $333 reported for 2025 was more than what 85% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $369 · 2021: $76.81 · 2022: $276 · 2023: $798 · 2024: $956 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $534.76 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $438.03 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $381.07 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $277.80 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $253.51 | 2022-2025 | Zerbaxa, Dificid, Verquvo |
| Pfizer INC. | $202.86 | 2019-2025 | |
| Allergan, INC. | $159.43 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $142.11 | 2019-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $105.83 | 2022-2023 | Givlaari |
| Alexion Pharmaceuticals, INC. | $95.50 | 2019-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $90.25 | 2019-2024 | Farxiga |
| Gilead Sciences, INC. | $82.67 | 2021-2023 | |
| Paratek Pharmaceuticals, INC. | $61.70 | 2023-2024 | Nuzyra |
| Scpharmaceuticals INC. | $30.03 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.02 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.16 | 2019-2020 | |
| Electromed, INC. | $19.79 | 2022 | |
| Glaxosmithkline, LLC. | $15.78 | 2025 | Trelegy Ellipta |
| Abbvie INC. | $14.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuxin Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.